Clinical Trials · NCT02200991

Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine

CompletedPhase 4Lixisenatide (Approved)
Phase
Phase 4
Recruitment status
Completed
Sponsor
Sanofi
Enrollment
136
Start date
Aug 2014
Locations
20 sites, Japan
Primary endpoint
Change from baseline in postprandial plasma glucose at Day 29 after a standardized breakfast
View Lixisenatide compound reference